Cytokinetics logo

Cytokinetics (CYTK) Q1 2026 Earnings

CYTK·Reported May 5, 2026·After market close

Cytokinetics reported Q1 2026 revenue of $19.4M (+1125.8% YoY), beat analyst consensus of $8.5M by $10.8M. Diluted EPS came in at $-1.67 (-22.8% YoY).

Revenue
$19.4Mbeat by $10.8M
Consensus: $8.5M
Diluted EPS
$-1.67met estimate
Consensus: $-1.67
SEC

SEC Filings

Earnings release8-K · 0001193125-26-206360
Quarterly report10-Q · 0001193125-26-206364

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Cytokinetics's Q1 2026 earnings report.

Cytokinetics (CYTK) reported Q1 2026 earnings on May 5, 2026 after market close.

Cytokinetics reported revenue of $19.4M and diluted EPS of $-1.67 for Q1 2026.

Revenue beat the consensus estimate of $8.5M by $10.8M. EPS beat the consensus estimate of $-1.67 by $0.00.

Compared to the same quarter a year prior, revenue grew 1125.8% from $1.6M a year earlier and diluted EPS declined 22.8% from $-1.36.

You can read the 8-K earnings release (0001193125-26-206360) and the 10-Q periodic report (0001193125-26-206364) directly on SEC EDGAR. The filing index links above go to sec.gov.